Application of Gypensapogenin A in medicine for treating rheumatoid arthritis

A technology for arthritis and rheumatoid arthritis, applied in the application field of Gypensapogenin A in the treatment of rheumatoid arthritis drugs, which can solve the problems of damage to the gastrointestinal mucosa, poor selectivity of action, ulcers, etc.

Active Publication Date: 2013-01-09
如东文园投资开发有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: the preparation of the compound Gypensapogenin A tablet involved in the present invention:

[0012] Take 20 grams of compound Gypensapogenin A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0013] Embodiment 2: The preparation of the compound Gypensapogenin A capsules involved in the present invention:

[0014] Get 20 grams of compound Gypensapogenin A, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.

[0015] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0016] Experimental example 1, the influence of Gypensapogenin A of the present invention on rat adjuvant arthritis

[0017] Grind Mycobacterium casei (Difco) and mix it with liquid paraffin to make 10mg / ml, and make Freund's complete adjuvant after autoclaving. Male SD rats were intradermally injected with 50ul of the above-mentioned adjuvant in the right hind paw, and at the same time, injected 50ul intradermally at the tail about 3cm away from the base of the tail. The difference of , represents the degree of swelling. On the 16th day after the adjuvant injection, the left hind paw of the rats was obviously swollen, and the rats were divided into groups according to the degree of swelling and body weight. The experimental group was orally given Gypensapogenin A 5.0, 10.0, 20.0 mg / kg of the present invention, and the positive control group was orally given diclofenac 10 mg / kg, the control group was given equal volume of distilled water, once a day, for 7 consecutive days, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides Gypensapogenin A for treating immune inflammation and application of Gypensapogenin A in a medicine for treating rheumatoid arthritis. Compared with terfenadine and diclofenac sodium, Gypensapogenin A has accurate curative effects. The application of Gypensapogenin B in preparing the medicine for treating rheumatoid arthritis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the rheumatoid arthritis inhibiting activity of Gypensapogenin A is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin A has outstanding actual characteristics. Meanwhile, Gypensapogenin A has outstanding progress when being used for preventing and treating rheumatoid arthritis.

Description

technical field [0001] The invention relates to the application of Gypensapogenin A in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a clinical common disease and frequently-occurring disease. Rheumatoid arthritis belongs to autoimmune disease and belongs to the category of immune inflammation. At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection. Therefore, compounds with well-defined components, controllable quality, safety and high efficiency have potential value in the development of drugs for rheumatoid arthritis. [0003] The compound Gypensapogenin A involved in the present invention was published in 2012 (Li, N. et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P29/00A61P19/02
Inventor 李丽丽施桦吴俊华
Owner 如东文园投资开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap